Menovazin

INSTRUCTIONS FOR MEDICAL USE OF THE MEDICINAL PRODUCT MENOVASIN

Composition:

Active substances: racemic menthol, procaine hydrochloride, benzocaine;

100 ml of solution contains 2.5 g of racemic menthol, 1 g of procaine hydrochloride, and 1 g of benzocaine;

Excipient: ethanol 70%.

Pharmaceutical form. External use alcoholic solution.

Main physicochemical properties: clear, colorless liquid with a characteristic odor of menthol.

Pharmacotherapeutic group.

Agents used locally for joint and muscular pain.

ATC code M02AX.

Pharmacological properties.

Pharmacodynamics.

The drug has anti-itching and local anesthetic effects. When applied to the skin and mucous membranes, it stimulates nerve endings, causing sensations of cold, mild burning, and tingling.

It exerts a mild analgesic effect.

Pharmacokinetics.

When applied locally, the drug does not enter the bloodstream.

Clinical characteristics.

Indications.

The drug is indicated for neuralgias, myalgias, and arthralgias.

Contraindications.

The drug is contraindicated in cases of hypersensitivity to procaine and to other components of the drug.

Special precautions.

Do not apply to damaged skin or skin with signs of allergy. Do not apply to facial skin.

Do not violate the instructions for use of the medicinal product, as this may harm health.

Interaction with other medicinal products and other forms of interaction.

Components of the drug (procaine, anestezin) weaken the antibacterial effect of sulfonamide drugs. They enhance the effects of drugs with local anesthetic action.

When using any other medicinal products simultaneously, inform your doctor.

Special precautions for use.

Use during pregnancy or breastfeeding.

During pregnancy or breastfeeding, the drug should be used only if the expected benefit to the mother outweighs the potential risk to the fetus or infant.

Ability to affect reaction rate while driving or operating machinery.

Has no effect.

Method of administration and dosage.

The drug is intended for topical use. Affected skin areas should be rubbed with Menovazin 2–3 times daily. The duration of treatment depends on the form and severity of the disease, the drug's effect, and the type of therapy (monotherapy or in combination with other medicinal agents).

Before the first use of Menovazin in a ball-type bottle, it is necessary to remove the protective membrane located under the ball applicator.

Children.

Do not use in children under 12 years of age.

Overdose.

With prolonged use, dizziness, general weakness, decreased arterial pressure, and allergic reactions may occur. If such symptoms occur, discontinue the drug, wash off any residue from the skin surface with water, and administer symptomatic therapy.

Side effects.

Allergic reactions are possible (hyperemia, skin irritation, itching sensation, rash, swelling, urticaria).

If any adverse events occur, consult a physician.

Shelf life.

For 40 ml or 100 ml bottles – 3 years.

For 50 ml ball bottles – 2 years.

The product must not be used after the expiry date stated on the packaging.

Storage conditions.

Store in original packaging at a temperature not exceeding 25 °C.

Keep out of reach of children.

Packaging.

40 ml or 100 ml in glass or polymer bottles; 50 ml in ball bottles.

Supply category. Over-the-counter.

Manufacturer: JSC "Lubnipharm".

Manufacturer's address and place of business.

16, Barvinkova St., Lubny, Poltava region, 37500, Ukraine.